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Background. This open-label, single-arm, two-stage, Phase II study investigated the eﬃcacy and safety of bi-weekly pemetrexed
combined with irinotecan, in patients with metastatic colorectal cancer (mCRC), after ﬁrst-line chemotherapy using FOLFOX
regimen. Patients and methods. Patients received pemetrexed 400mg/m2 as a 10-minute intravenous infusion (with vitamin
supplementation) followed by irinotecan 180mg/m2 as a 90-minute infusion on day 1 of a 14-day cycle, for a maximum of 12
cycles. The primary endpoint was response rate (RR; H0 ≤ 5%, Ha ≥ 20%, α = 0.05, power = 90%). Secondary endpoints were
duration of response, progression-free survival (PFS), overall survival (OS), and toxicities. Results. Partial response was observed
in six out of 44 patients enrolled in the study (RR = 13.6%). The median PFS and OS were 4.0 and 13.9 months, respectively. The
most common grade 3-4 toxicities were fatigue: 20.5% of patients, neutropenia: 18.6%, diarrhea: 13.6%, elevated transaminases:
9.5%, anemia: 9.3%, and vomiting: 6.8%. Conclusion. Pemetrexed plus irinotecan administered every two weeks is an active and
well-tolerated regimen in mCRC patients pretreated with FOLFOX regimen. However, this regimen does not seem to provide
clinically relevant advantage over historical data of a classical FOLFIRI regimen.
1.Introduction
Colorectal cancer accounts for 10% to 15% of all cancers
and is the second leading cause of cancer deaths in west-
ern countries. Approximately half of all patients develop
metastatic disease [1]. In many patients, disease is too
advanced for any treatment other than palliative therapy.
Eﬃcacy of front-line chemotherapy for the treatment of
patients with metastatic colorectal cancer (mCRC) has been
improved by the use of combined treatments of irinote-
can or oxaliplatin with ﬂuoropyrimidines. The addition
of irinotecan to bolus 5-ﬂuorouracil/leucovorin (5-FU/LV)
increased median survival in patients with mCRC from
12 to 14.8 months [2]. This rate was increased further
by combining irinotecan or oxaliplatin with infusion-based
5-FU/LV however, doublets such as irinotecan plus infu-
sional 5-FU/LV (FOLFIRI) or oxaliplatin plus infusional 5-
FU/LV (FOLFOX) prolonged median survival to more than
20 months [3–6]. Both regimens, FOLFOX and FOLFIRI,
are recognized as standard ﬁrst-line therapies for mCRC [7].
However, the 5-year survival rate remains poor (less than
10%).
The clinical beneﬁt of second-line therapy in patients
with progressive disease remains unsatisfactory. Few data are
available about irinotecan-based chemotherapy in patients
previously treated with FOLFOX. The FOLFIRI regimen
achieved only 5% to 10% response rate after FOLFOX in
heavily pretreated patients, and optimization of irinotecan-
based regimens is clearly needed [8, 9].2 Journal of Oncology
Pemetrexed (Alimta) is a multitargeted antifolate agent
that inhibits several key folate-dependent enzymes required
for de novo purine and/or pyrimidine biosynthesis, includ-
ing thymidylate synthase (TS), dihydrofolate reductase
(DHFR), and glycinamide ribonucleotide formyltransferase
(GARFT) [10]. Pemetrexed has shown broad clinical anti-
tumor activity in patients with colorectal, pancreatic, and
breast cancers [11] and has received regulatory approvals
for treating patients with malignant mesothelioma and
nonsmall cell lung cancer [12]. Pemetrexed 500–600mg/m2
administered every three weeks showed single-agent activity
as ﬁrst-line treatment for advanced CRC in two phase II
trials [13, 14]. The objective responses rates were 15%
in the American study [14] and 17% in the Canadian
study [13] and the median overall survival times were
16.2 and 15.1 months, respectively. The major toxicities of
pemetrexed are myelosuppression, skin rash, and mucositis,
with neutropenia being the primary dose-limiting toxicity
[15]. An elevated level of plasma homocysteine was found
to be a signiﬁcant risk factor for treatment-related toxicities
[16]. Supplementation with vitamin B12 and folic acid has
beenshowntolowerplasmahomocysteinelevelandimprove
the toxicity of pemetrexed.
The distinct mechanisms of action and patterns of
resistance displayed by pemetrexed and irinotecan make
them attractive agents for combination therapy in mCRC
patients. The combination of pemetrexed and irinotecan,
administered every three weeks, was shown to be feasible
in phase I studies [17, 18]. In the phase I/II study reported
by Hochster et al., pemetrexed 500mg/m2 followed by
irinotecan 300mg/m2 on day 1, every 21 days, induced an
objective response rate of 11% in 35 patients previously
treated with 5-FU-based chemotherapy for advanced disease
[17].
This multicenter, nonrandomized, open-label, single-
arm phase II study was initiated to evaluate the eﬃcacy and
safety of bi-weekly pemetrexed plus irinotecan, after failure
to the FOLFOX regimen in patients with mCRC.
2. Patientsand Methods
2.1. Patients. Male and female patients of at least 18
years of age, with histologically or cytologically conﬁrmed
mCRCprogressiveafterﬁrst-linechemotherapywithasingle
FOLFOX regimen (5-FU, leucovorin, and oxaliplatin), were
eligible for the study. Further inclusion criteria included the
following: ECOG (Eastern Cooperative Oncology Group)
performance status of 0, 1, or 2; life expectancy of at least
12 weeks; at least one site of measurable metastatic lesion; no
prior radiation therapy to bone marrow exceeding 25% of
hematopoietic reserves and adequate hematologic (absolute
neutrophilcount[ANC] ≥1.5 ×109/L,plateletcount ≥ 100×
109/L, and hemoglobin ≥9 g/dL), hepatic (serum bilirubin
≤ 1.5 times the upper limit of normal (ULN); alkaline
phosphatase (ALP), aspartate transaminase (ASAT) and
alanine transaminase (ALAT) ≤ 3.0× ULN or ≤ 5× ULN in
case of hepatic metastases) and renal (calculated creatinine
clearance (CrCl) ≥ 45mL/min) functions. Exclusion criteria
included pregnant or breast-feeding women, prior treatment
with irinotecan (except adjuvant treatment administered
more than 6 months before study entry), documented
brain metastases not amenable to surgery or unstable after
radiation, unwillingness or inability to take vitamin B12
or folic acid, and history of weight loss (≥10%) over the
previous 6 weeks before study entry.
ThestudywasconductedinaccordancewiththeDeclara-
tion of Helsinki and the guidelines of Good Clinical Practice.
The institutional review boards of participating centers
approved the study, and patients gave written informed
consent before enrollment.
2.2. Treatment Plan. All patients received 400mg/m2 peme-
trexed (Alimta, Eli Lilly and Company, Indianapolis, Indi-
ana) as a 10-minute intravenous (i.v.) infusion followed
by 180mg/m2 irinotecan as a 90-minute i.v. infusion on
day 1 of a 14-day cycle. Cycles were repeated until dis-
ease progression, unacceptable toxicity, and investigator or
patient decision, with a maximum of 12 cycles. Folic acid
oral supplementation of 350–600μg or equivalent was given
daily beginning 1 to 2 weeks prior to Day 1 of Cycle 1 and
continuing daily until 3 weeks after the last pemetrexed dose.
Vitamin B12 1000μg was injected intramuscularly 1 to 2
weeks prior to the ﬁrst pemetrexed dose then every 9 weeks
until 3 weeks after the ﬁnal dose. Dexamethasone (4mg or
equivalent) was administered orally twice daily on the day
before, the day of, and the day after each dose of pemetrexed.
Dose adjustments or delays during the study were based
on hematologic and/or nonhematologic toxicities in the
preceding cycle, graded according to the National Cancer
Institute-Common Terminology Criteria for Adverse Events
(NCI-CTCAE, version 3.0, 2003). Patients were required to
have an ANC of at least 1.5 ×109/L and a platelet count of at
least75×109/Lbeforetreatmentontheﬁrstdayofeachcycle.
The doses of both drugs were delayed (until resolution or
returntobaseline)andmodiﬁedforeitherANC< 1.0×109/L
and a platelet count of ≥ 50×109/L (25% dose reduction) or
a platelet count of <50 ×109/L (50% reduction). Similarly,
treatment was delayed for insuﬃcient folic acid or vitamin
B12 supplementation, grade 3/4 nonhematologic toxicities
(except for grade 3 transaminase elevation, nausea, vomit-
ing, and alopecia), or calculated CrCl <45mL/min. When
nonhematologic toxicities resolved, therapy resumed at 75%
of the previous level for grade 3 diarrhea (only the dose
of irinotecan was reduced for these patients), grade 3 or 4
vomiting despite antiemetic premedication, and any other
grade 3/4 nonhematologic toxicity deemed appropriate.
Therapy resumed at 50% of the previous level for grade 3
or 4 mucositis or grade 4 diarrhea (irinotecan only). Dose
reescalation was not allowed. Any patient requiring a third
dose reduction was discontinued from the study.
Concomitant treatments included atropine for choliner-
gic symptoms (preventive treatment was given if severe acute
cholinergic symptoms were experienced during a previous
cycle)andloperamideasacurativetreatment.Premedication
withanantiemeticregimenincludinganHT3antagonistwas
recommended.Journal of Oncology 3
2.3. Study Assessments. Disease status was assessed at base-
line by a complete medical history and physical examination
withabdominalcomputedtomography(CT)scansandchest
X-ray, performance status (PS) measurement and complete
bloodchemistryandhematology.Duringtreatment,physical
examinations and PS assessments, hematology and serum
chemistry were carried out before each cycle. CT-scans and
C E Al e v e l sw e r ep e r f o r m e de v e r y4c y c l e st od o c u m e n t
response, then 30 days after the last dose of study drugs and
every 3 months for two years.
2.4. Evaluation of Response and Toxicity. Objective tumor
response was rated using Response Evaluation Criteria in
Solid Tumors (RECIST) guidelines [19]. Complete response
(CR) was deﬁned as the disappearance of all clinical and
radiological evidence of target lesions; partial response (PR)
asa ≥30%decreaseintheoverallsumofthelongestdiameter
of the target lesion(s) taking as reference the baseline sum,
and progressive disease (PD) as a ≥20% increase in the
overall sum of the longest diameter of the target lesion(s)
taking as reference the smallest sum recorded since the
treatment started. In case of PR or CR, a second assessment
was required 4 weeks later for conﬁrmation of response. The
duration of response was deﬁned as the time from the ﬁrst
objective status assessment of CR or PR to the ﬁrst time
of progression or death due to any cause. The duration of
response was censored at the date of the last follow-up visit
for patients who neither had progression nor died due to
any cause. Progression-free survival (PFS) was deﬁned as the
timefromstudyenrollmenttotheﬁrstobservationofdisease
progression or death due to any cause. PFS was censored at
the date of the last follow-up visit for patients who neither
had progression nor died due to any cause. Overall survival
was the time from study enrollment to time of death from
any cause. Overall survival was censored at the date of the
last follow-up visit for patients who had been still alive or
lost to follow-up.
Toxicity was recorded before each cycle and graded
according to the NCI-CTCAE (version 3.0, 2003).
2.5.StatisticalAnalysis. Forty-ﬁvepatientshadtobeenrolled
in this single-arm, two-stage, sequential phase II study with
the possibility of stopping the study early because of lack of
eﬃcacy assuming a 10% drop-out rate [20]. A total of 20
evaluable patients were to be entered in the ﬁrst stage. If
at least one response was observed in the ﬁrst 20 patients,
20 additional patients evaluable for response were to be
accrued (total of 40 evaluable patients). If fewer than 5 of 40
patientsrespondedtotherapy,theregimenhadtobedeemed
not worthy of any further investigation in this patient
population, unless clinical considerations suggest otherwise.
If responses were seen in greater than or equal to 5 of 40
patients, the regimen was to be recommended for further
study. If the true response rate was 5%, the probability that
this procedure would conclude that the regimen was worthy
of further study was 0.05 (signiﬁcance). If the true response
rate was 20%, this procedure had power of 90% to conclude
that the regimen was worthy of further study.
Table 1: Patient characteristics (N = 44).
N (%)
Age, years Median 63.0
Range 33–81
Sex Male 31 (70.5%)
Female 13 (29.5%)
ECOG
performance
status
0 24 (54.5%)
1 15 (34.1%)
2 5 (11.4%)
Primary site
Colon 22 (50.0%)
Rectum 20 (45.5%)
Colorectal 2 (4.5%)
Metastatic sites
Liver 31 (70.5%)
Lung 18 (40.9%)
Lymph nodes 8 (18.2%)
Other
(mediastinum,
pelvis,
perineum)
4 (9.1%)
Peritoneum 2 (4.5%)
Number of
target lesions
1 11 (25.0%)
2 12 (27.3%)
3 10 (22.7%)
4 or more 11 (25.0%)
Prior therapy
Surgery 38 (86.4%)
Radiotherapy 11 (25.0%)
Chemotherapy
Metastatic 44 (100.0%)
Time from
initial diagnosis
to inclusion,
months
Median 17.0
Range 2.8–81.1
Abbreviation: ECOG: Eastern Cooperative Oncology Group.
The primary endpoint was the best overall objective
response rate (complete plus partial responses) and its exact
95%conﬁdenceinterval(CI)basedonFdistributionmethod
(Leemis and Trivedi, 1996) was presented. All patients who
had received at least one complete cycle were included in
the primary outcome analysis. Secondary outcomes were
PFS, overall survival, and incidence of adverse events. The
distribution of time-to-event endpoints was estimated using
the Kaplan-Meier method (Kaplan and Meier, 1958), 95% CI
for the quartiles was based on the sign test (Brookmeyer and
Crowley,1982).Fortoxicityanalysis,theworstgradeforeach
patient was used.
3. Results
Forty-six patients were entered in the study by six French
centers between 06/2004 and 01/2006. Two patients were
withdrawn before the beginning of the study treatment
due to unmet protocol entry criteria and patient’s decision4 Journal of Oncology
Table 2: Best conﬁrmed response in patients who received at least
one complete cycle of chemotherapy (N = 44).
Best tumor response Number of patients %
Partial response 6 13.6
Stable disease 18 40.9
Progressive disease 15 34.1
Unknown 5 11.4
(44 patients included). Forty-four patients received at least
one complete cycle of chemotherapy.
3.1. Patient Characteristics. The baseline characteristics of
the patients (N = 44) are summarized in Table 1.T h e
majority of the patients were male (70.5%) and the median
age was 63 years (range: 33 to 81 years). The median time
from initial diagnosis to inclusion was 17 months. The
majority of patients (75.0%) had two or more synchronous
metastatic sites with liver (70.5%) and lung (40.9%) as the
most common sites of metastases. Liver-only disease was
present in 11 patients. The majority of patients (86.4%)
underwent prior surgery while 29.5% had received adjuvant
treatment, and all had previously been treated with a
FOLFOX (n = 41) or a XELOX (n = 3) regimen for metastatic
disease.
3.2. Treatment Delivery. The median number of treat-
ment cycles administered was 4.5 (range: 1 to 14 cycles).
The median relative dose intensities (RDI—actual/planned
doses) were 96.5% for pemetrexed (range: 47.9% to 102.8%)
and 95.2% for irinotecan (range: 61.8% to 102.5%). The
doses of pemetrexed and irinotecan had to be reduced due
to the occurrence of an adverse event for 18% and 23% of
patients, respectively. The cycles were delayed for 66% of
patients, mainly due to scheduling conﬂict. Seven patients
(15.9%) completed the study protocol and 37 patients
discontinued the study early due to lack of eﬃcacy (n = 21),
patient’sdecision(n=6),physician’sdecision(n=4),adverse
event (n = 4), or death (n = 2).
3.3. Eﬃcacy. One partial response was observed in the ﬁrst
20 patients, and thus it allowed to continue enrollments up
to a total of 44 patients in accordance with the protocol. In
the population of patients receiving at least one complete
cycle of chemotherapy (N = 44), the best overall response
rate was 13.6% (95% CI, 5.2% to 27.4%). Table 2 provides
the best conﬁrmed response information. There were 6
partial responses (13.6%), 18 patients (40.9%) had stable
disease, 15 patients (34.1%) had progressive disease, and
response was unknown for 5 patients (11.4%). The median
duration of responses was 7.8 months (95% CI, 3.5 to 11.6
months). The median PFS was 4.0 months (95% CI, 2.0 to
4.8 months) (Figure 1). The median overall survival was 13.9
months (95% CI, 10.0 to 19.8 months) (Figure 2). Thirty-
two patients received third-line chemotherapy.
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Figure 1: Kaplan-Meier analysis of progression-free survival (N =
44).
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Figure 2: Kaplan-Meier analysis of overall survival (N = 44).
3.4. Safety. Table 3 summarizes the grade 3 or 4 toxicities
occurring during the study. The most common grade 3 or
4 adverse events possibly related to study drugs were fatigue
(20.5% of patients), neutropenia (18.6%), diarrhea (13.6%),
elevatedALAT (9.5%),anemia (9.3%),and vomiting (6.8%).
Eight patients (18.2%) experienced at least one serious
adverse event (SAE) related to study drugs with anemia,
diarrhea, vomiting, and dehydration as the most common
SAE. Four patients (9.1%) experienced an AE leading toJournal of Oncology 5
study discontinuation. No toxic death was reported during
the study period.
4. Discussion
This open, nonrandomized, multicenter, single-arm phase
II study assessed the eﬃcacy and safety of pemetrexed
plus irinotecan combination as second-line treatment of
patients with metastatic colorectal cancer. The combination
of pemetrexed plus irinotecan administered every two weeks
with vitamin supplementation is an eﬀective and acceptably
tolerated regimen in mCRC patients previously treated with
FOLFOX. The objective response rate of the combination
was 14% and stable disease was reported in 41% of
patients. The median PFS and overall survival were 4.0
months and 13.9 months, respectively. These results are
close to those reported with pemetrexed plus irinotecan
administered every three weeks in patients with advanced
CRCpreviouslytreatedwith5-FU-basedchemotherapy[17].
In 35 patients treated with pemetrexed 500mg/m2 followed
by irinotecan 300mg/m2 with vitamin supplementation,
the objective response rate was 11.4% and the median
time to progression and overall survival was 3.7 and 8.1
months, respectively. Usually, a second-line irinotecan-based
combination is indicated for mCRC patients after FOLFOX
ﬁrst-line failure. The eﬃcacy of pemetrexed plus irinotecan
in the present study seems to be comparable to historical
data for FOLFIRI regimens. Andr´ e et al. reported an overall
response rate of 6% and a median survival of 9.9 months in
33mCRC patients treated by FOLFIRI as third-line therapy
[8]. Tournigand et al. demonstrated that FOLFIRI had a low
response rate when given after ﬁrst-line FOLFOX (4%) [9].
FOLFIRI-2 regimen (leucovorin, ﬂuorouracil, irinotecan,
andhydroxyurea)inducedanobjectiveresponserateof17%,
a median PFS of 4.1 months, and a median survival of 9.7
months in 29 patients refractory to 5-FU and oxaliplatin
[21]. FOLFIRI-3, in which irinotecan is administered as
two infusions (half dose before 5-FU and half dose at the
end of the 5-FU infusion), induced a response rate of 23%
in 65mCRC patients pretreated with FOLFOX, a median
progression-free survival of 4.7 months, and a median
survival of 10.5 months [22].
The choice of a second-line therapy in mCRC is now
more and more complex. It has to be deﬁned for each
patient based on the previous received treatments (adjuvant
as well as ﬁrst-line metastatic), the available active drugs
in CRC (conventional chemotherapies as well as targeted
therapies), and some genomic properties of the tumor.
Actually, anti-VEGF bevacizumab and anti-EGFr cetuximab
or panitumumab become available in the treatment of
mCRC and could also be indicated as second-line treatments
in combination with conventional chemotherapy [23, 24].
To date, anti-VEGF drugs administration is not limited by
validated genomic alteration, while anti-EGFr use should
be restricted to tumors with a wild-type KRAS phenotype.
To our knowledge, no data concerning combination of
pemetrexed with targeted drugs in mCRC is available.
Interestingly, activity of pemetrexed was demonstrated as
Table 3: Number of patients who experienced a grade 3 or 4
toxicity.
NCI-CTCAE grade 3-4 toxicity Grade 3 Grade 4
Hematological toxicity
Anemia 3 (7.0%) 1 (2.3%)
Leucopenia 1 (2.3%) 2 (4.7%)
Neutropenia 5 (11.6%) 3 (7.0%)
Thrombocytopenia 1 (2.3%) 0 (0.0%)
Nonhematological toxicity
Fatigue 9 (20.5%) 0 (0.0%)
Nausea 2 (4.5%) 0 (0.0%)
Diarrhea 5 (11.4%) 1 (2.3%)
Vomiting 3 (6.8%) 0 (0.0%)
Anorexia 2 (4.5%) 0 (0.0%)
Mucositis/stomatitis 2 (4.5%) 0 (0.0%)
Dehydration 2 (4.5%) 0 (0.0%)
Febrile neutropenia 1 (2.3%) 0 (0.0%)
Infection 0 (0.0%) 1 (2.3%)
Rash 1 (2.3%) 0 (0.0%)
Biochemistry
ALAT increase 4 (9.5%) 0 (0.0%)
Hyperbilirubinemia 2 (4.8%) 0 (0.0%)
Hypokalemia 2 (4.8%) 0 (0.0%)
Alkaline phosphatase 1 (2.4%) 0 (0.0%)
Hyponatremia 1 (2.4%) 0 (0.0%)
Abbreviations:NCI-CTCAE:NationalCancerInstitute-CommonTerminol-
ogy Criteria for Adverse Events; ALAT: alanine aminotransferase.
related to polymorphism of thymidylate synthase (TS) and
methylenetetrahydrofolate reductase (MTHFR) in nonsmall
cell lung cancer [25]. Such impact of TS and MTHFR
polymorphisms deserves to be analyzed in colon cancer
and may help in the deﬁnition of subgroups of patients
who could better beneﬁt from pemetrexed administration in
mCRC.
The tolerance proﬁle of every two-week pemetrexed
plus irinotecan combination was acceptable and manage-
able in mCRC patients previously treated with FOLFOX.
Myelosuppression, general disorders, and gastrointestinal
disorders were the most common toxicities resulting from
the combination therapy. The most common grade 3-4
toxicities were fatigue (20%), neutropenia (19%), diarrhea
(14%), elevated ALAT (9.5%), anemia (9%), and vomiting
(7%). Grade 4 toxicity was infrequent and only one patient
experienced febrile neutropenia. The toxicity proﬁle of
the same combination administered every three weeks as
second-line therapy was similar except for the incidence of
fatigue, which was higher in the every-two week schedule
[17]. However, the grade 3-4 toxicities (mainly fatigue
and diarrhea) led to early treatment discontinuation in 10
patients (23%). This, combined with a usual short PFS in
second-line mCRC patients, explained the low 4.5 median
number of administered cycles.
In conclusion, pemetrexed plus irinotecan administered
every two weeks is an active and well-tolerated regimen in6 Journal of Oncology
mCRC patients pretreated with FOLFOX regimen. However,
based on historical data, this regimen seems not to provide
clinically relevant advantage over combinations of 5-FU
and irinotecan in second-line mCRC treatment. This was
also the case in ﬁrst-line therapy, where the every-three-
week pemetrexed plus irinotecan regimen (ALIRI) did not
improve upon the eﬃcacy and safety observed with FOLFIRI
[26]. These data do not incite to perform randomized stud-
ies comparing pemetrexed-irinotecan to 5-FU-irinotecan.
However, this combination could be of interest in patients
who experienced severe toxicities when treated with ﬂuo-
ropyrimidines, or in patients with ﬂuoropyrimidines and/or
targeted drugs contraindication. Additional data concerning
combinations of pemetrexed and biologics and concerning a
possible selection of patients who could better beneﬁt from
pemetrexed, based on genomic properties of the tumor, are
needed.
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